We are live on ! Find out more
SNDX icon

Syndax Pharmaceuticals
SNDX

72 hedge funds and large institutions have $128M invested in Syndax Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 26 increasing their positions, 14 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

86% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 14

13% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 8

12% more call options, than puts

Call options by funds: $3.39M | Put options by funds: $3.02M

1% more funds holding

Funds holding: 71 → 72 (+1)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.21% less ownership

Funds ownership: 63.37% → 63.16% (-0.21%)

20% less capital invested

Capital invested by funds: $160M → $128M (-$31.8M)

Holders
72
Holders Change
+1
Holders Change %
+1.41%
% of All Funds
1.58%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
9
Increased
26
Reduced
14
Closed
8
Calls
$3.39M
Puts
$3.02M
Net Calls
+$366K
Net Calls Change
+$58K

Top Buyers

1
BC
Boxer Capital
California
+$3.64M
2
State Street
State Street
Massachusetts
+$829K
3
Renaissance Technologies
Renaissance Technologies
New York
+$593K
4
Northern Trust
Northern Trust
Illinois
+$507K
5
OAM
Oxford Asset Management
United Kingdom
+$457K

Top Sellers

1
6CM
683 Capital Management
New York
-$4.05M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$2.05M
3
Wellington Management Group
Wellington Management Group
Massachusetts
-$1.64M
4
USAA
United Services Automobile Association
Texas
-$1.15M
5
CCIA
Campbell & Co Investment Adviser
Maryland
-$367K
Name Holding Trade Value Shares
Change 		Change in
Stake
Wellington Management Group
1
Wellington Management Group
Massachusetts
$23.1M -$1.64M -179,759 -5%
MAM
2
MPM Asset Management
Massachusetts
$16.2M – – –
BI
3
BVF Inc
California
$13.2M – – –
BlackRock
4
BlackRock
New York
$12.8M +$290K +31,797 +2%
Adage Capital Partners
5
Adage Capital Partners
Massachusetts
$9.34M -$2.05M -225,000 -15%
6CM
6
683 Capital Management
New York
$8.75M -$4.05M -444,307 -27%
Vanguard Group
7
Vanguard Group
Pennsylvania
$8.01M +$392K +42,998 +4%
Dimensional Fund Advisors
8
Dimensional Fund Advisors
Texas
$7.15M +$114K +12,490 +1%
Renaissance Technologies
9
Renaissance Technologies
New York
$3.71M +$593K +65,100 +15%
State Street
10
State Street
Massachusetts
$3.1M +$829K +91,018 +28%
BC
11
Boxer Capital
California
$2.99M +$3.64M +400,000 New
Geode Capital Management
12
Geode Capital Management
Massachusetts
$2.14M +$161K +17,681 +7%
Northern Trust
13
Northern Trust
Illinois
$1.82M +$507K +55,631 +30%
SI
14
Sofinnova Investments
California
$1.82M +$3.83K +421 +0.2%
O
15
OrbiMed
New York
$1.58M – – –
PAM
16
Panagora Asset Management
Massachusetts
$1.57M +$109K +11,986 +6%
Macquarie Group
17
Macquarie Group
Australia
$1.34M – – –
N
18
Nuveen
North Carolina
$1.11M +$362K +39,756 +36%
OAM
19
Oxford Asset Management
United Kingdom
$811K +$457K +50,191 +86%
Morgan Stanley
20
Morgan Stanley
New York
$683K +$279K +30,680 +51%
Jacobs Levy Equity Management
21
Jacobs Levy Equity Management
New Jersey
$596K +$435K +47,712 +149%
Bank of New York Mellon
22
Bank of New York Mellon
New York
$540K +$13.2K +1,446 +2%
Charles Schwab
23
Charles Schwab
California
$375K – – –
MA
24
MCF Advisors
Kentucky
$284K – – –
JP Morgan Chase
25
JP Morgan Chase
New York
$271K +$281K +30,833 +558%
1
2 3 4

SNDX Hedge Fund Activity: Q3 2019 in Review

72 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Syndax Pharmaceuticals (SNDX) for Q3 2019, worth a combined $128M — down 20% from $160M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new SNDX positions and 8 closed out — a net gain of 1 holder — while 26 added to existing stakes and 14 trimmed.

The largest buyer was Boxer Capital, opening a new position worth an estimated $3.64M. The largest seller was 683 Capital Management, cutting an estimated $4.05M.

  • 72 institutional investors held Syndax Pharmaceuticals (SNDX) as of Q3 2019, up from 71 in Q2 2019.
  • Funds reported $128M of Syndax Pharmaceuticals stock for Q3 2019, down 20% quarter-over-quarter.
  • 9 funds opened new Syndax Pharmaceuticals positions in Q3 2019 and 8 closed out, a net change of +1 holder.
  • The largest Syndax Pharmaceuticals buyer in Q3 2019 was Boxer Capital, an estimated $3.64M added.
  • The largest Syndax Pharmaceuticals seller in Q3 2019 was 683 Capital Management, an estimated $4.05M sold.

Based on aggregated 13F filings for Q3 2019.